July 2007
Drug Topics;7/9/2007, Vol. 151 Issue 13, p42
Trade Publication
Product Review
The article evaluates the Norditropin Injection somatotropin from Novo Nordisk.


Related Articles

  • Novo files growth hormone patent infringement suit in US.  // Chemical Market Reporter;10/13/97, Vol. 252 Issue 15, p24 

    Discloses that Novo Nordisk A/S has filed a patent infringement lawsuit in a US District Court against four companies that manufacture and/or market biosynthetic human growth hormones that compete with Novo Nordisk's product in the United States. List of companies cited in the lawsuit; Details...

  • Novo Nordisk to market human growth hormone.  // Drug Topics;1/6/97, Vol. 141 Issue 1, p10 

    Reports on a United States Court of Appeals' decision allowing Novo Nordisk AS to market its recombinant human growth hormone, Norditropin.

  • The 90-Day Launch. Lennox, Mads; Walton, Deborah // Pharmaceutical Executive;Jun2002 Supplement, Vol. 23, p124 

    Presents a case study on the launching of Novo Nordisk's human growth hormone Norditropin. Steps taken by Sentrix Global Health Communications in launching Norditropin; Information on Norditropin; Contribution of the brand icon NordiHero to the launching Norditropin.

  • FDA approves growth hormone.  // Drug Topics;5/22/95, Vol. 139 Issue 10, p8 

    Reports on the Food and Drug Administration's (FDA) approval of Novo Nordisk's growth hormone Norditropin. Drug's indication for the long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

  • Pharma & Fine Chemicals: Market Briefs.  // Chemical Market Reporter;09/20/99, Vol. 256 Issue 12, p12 

    Presents news briefs from the pharmaceuticals and fine chemicals industries as of September 20, 1999. Acquisition of marketing and distribution rights for Sanofi-Sythelabo's Dynabac in the United States by Muro Pharmaceutical Inc.; Marketing approval received by Nordisk AS for its liquid growth...

  • NEW STORAGE GUIDELINES.  // Drug Topics;2/6/2006, Vol. 150 Issue 3, p52 

    The article reports that Princeton, New Jersey-based Novo Nordisk AS has received new storage guidelines approved by the U.S. Food and Drug Administration. The new storage guidelines are intended for the company's 5- and 10-milligram Norditropin NordiFlex prefilled multi-dose disposable growth...

  • NEW DEVICES.  // Drug Topics;2/6/2006, Vol. 150 Issue 3, p55 

    The article announces the addition of the 10-milligram pen to the line of Norditropin Nordiflex 5-milligram and 10-milligram pens from Novo Nordisk AS in Princeton, New Jersey. The new container size will allow physicians to more closely calculate doses of growth hormone based on weight and age,...

  • Enzyme unit closes.  // Chemical Week;3/6/1996, Vol. 158 Issue 9, p32 

    Reports on the plan of Denmark firm Novo Nordisk to close its manufacturing unit Novo Nordisk Biochemicals K.K. in Hokkaido, Japan. Reasons for the closure; Plans for affected employees.

  • Assisted-living facilities to test insulin-delivery pen. Tarlach, Gemma M. // Drug Topics;3/16/98, Vol. 142 Issue 6, p45 

    Reports that Novo Nordisk's Novolin Prefilled insulin-delivery system will be test marketed by the joint forces of Novo Nordisk Pharmaceuticals, Marriott Senior Living Services, and Medicine-On-Time. Details on the cost effectiveness of pen-style delivery system; Information on how Novo Nordisk...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics